Colleen Sjogren
Vermogen: 559 440 $ op 31-08-2026
Vermogen: 559 440 $ op 31-08-2026
Ms. Colleen Sjogren is a Chief Commercial Officer at Nuvation Bio, Inc. Ms. Sjogren was previously employed as a Senior Vice President-Sales by Madrigal Pharmaceuticals, Inc., a VP-US Sales, Sales Training & Meeting Planning by Mirati Therapeutics, Inc., and a Vice President-National Cell Therapy & Sales by Kite Pharma, Inc. She received her undergraduate degree from Bryant University.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 27-02-2026 | 84.000 ( 0,02% ) | 559 440 $ | 31-08-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| NUVATION BIO INC. | Corporate Officer/Principal | 28-03-2024 |
| Bedrijven | Functie | Einde |
|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | Verkoop & Marketing | 01-12-2023 |
| MIRATI THERAPEUTICS | Verkoop & Marketing | 01-09-2022 |
| KITE PHARMA INC | Verkoop & Marketing | 01-04-2021 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops cancer therapies | Health Technology |
Bryant University
Bryant University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kite Pharma, Inc.
Kite Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company which engages in the development of novel cancer immunotherapeutic products | Health Technology |
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops small-molecule drugs for cardiovascular, metabolic and liver diseases | Health Technology |
Nuvation Bio, Inc.
Nuvation Bio, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops oncology related novel therapeutic candidates | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau